The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Adma Biologics Inc’s stock clocked out at $17.63, up 3.77% from its previous closing price of $16.99. In other words, the price has increased by $3.77 from its previous closing price. On the day, 2.9 million shares were traded. ADMA stock price reached its highest trading level at $17.895 during the session, while it also had its lowest trading level at $16.86.
Ratios:
To gain a deeper understanding of ADMA’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 46.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 63.97. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 5.33. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.21.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 15 ’25 when Grossman Adam S sold 21,000 shares for $16.88 per share. The transaction valued at 354,480 led to the insider holds 2,031,850 shares of the business.
Grossman Adam S sold 21,000 shares of ADMA for $391,860 on Jul 15 ’25. The President and CEO now owns 2,037,850 shares after completing the transaction at $18.66 per share. On Jul 15 ’25, another insider, Grossman Adam S, who serves as the Director and Officer of the company, bought 63,000 shares for $18.68 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 4207064576 and an Enterprise Value of 4200599552. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.76, and their Forward P/E ratio for the next fiscal year is 19.44. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.69. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.87 while its Price-to-Book (P/B) ratio in mrq is 10.60. Its current Enterprise Value per Revenue stands at 8.859 whereas that against EBITDA is 25.684.
Stock Price History:
The Beta on a monthly basis for ADMA is 0.53, which has changed by -0.016731739 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, ADMA has reached a high of $25.67, while it has fallen to a 52-week low of $13.50. The 50-Day Moving Average of the stock is -3.77%, while the 200-Day Moving Average is calculated to be -6.25%.
Shares Statistics:
It appears that ADMA traded 3.04M shares on average per day over the past three months and 4440810 shares per day over the past ten days. A total of 239.38M shares are outstanding, with a floating share count of 230.44M. Insiders hold about 3.43% of the company’s shares, while institutions hold 87.73% stake in the company. Shares short for ADMA as of 1753920000 were 13736123 with a Short Ratio of 4.51, compared to 1751241600 on 16238070. Therefore, it implies a Short% of Shares Outstanding of 13736123 and a Short% of Float of 7.0700005.
Earnings Estimates
The current rating of Adma Biologics Inc (ADMA) is the result of assessments by 2.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.18, with high estimates of $0.18 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.59 and $0.54 for the fiscal current year, implying an average EPS of $0.56. EPS for the following year is $0.93, with 3.0 analysts recommending between $0.97 and $0.87.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $131.2M. It ranges from a high estimate of $133.3M to a low estimate of $130.1M. As of the current estimate, Adma Biologics Inc’s year-ago sales were $119.84MFor the next quarter, 3 analysts are estimating revenue of $137.17M. There is a high estimate of $139.8M for the next quarter, whereas the lowest estimate is $133.5M.
A total of 4 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $509.61M, while the lowest revenue estimate was $503.5M, resulting in an average revenue estimate of $506.3M. In the same quarter a year ago, actual revenue was $426.45MBased on 4 analysts’ estimates, the company’s revenue will be $637.85M in the next fiscal year. The high estimate is $647.21M and the low estimate is $631M.
